Morgan Stanley’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-401,481
| Closed | -$915K | – | 8071 |
|
|
2024
Q2 | $915K | Buy |
401,481
+226,144
| +129% | +$864K | ﹤0.01% | 5016 |
|
|
2024
Q1 | $757K | Sell |
175,337
-164,779
| -48% | -$574K | ﹤0.01% | 5120 |
|
|
2023
Q4 | $1.04M | Buy |
340,116
+304,973
| +868% | +$573K | ﹤0.01% | 5273 |
|
|
2023
Q3 | $50.6K | Sell |
35,143
-112,257
| -76% | -$217K | ﹤0.01% | 6164 |
|
|
2023
Q2 | $367K | Sell |
147,400
-115,663
| -44% | -$316K | ﹤0.01% | 5369 |
|
|
2023
Q1 | $705K | Sell |
263,063
-107,610
| -29% | -$517K | ﹤0.01% | 5058 |
|
|
2022
Q4 | $2.01M | Buy |
370,673
+32,379
| +10% | +$271K | ﹤0.01% | 4461 |
|
|
2022
Q3 | $4.22M | Buy |
338,294
+155,643
| +85% | +$1.78M | ﹤0.01% | 3832 |
|
|
2022
Q2 | $903K | Sell |
182,651
-92,307
| -34% | -$511K | ﹤0.01% | 5076 |
|
|
2022
Q1 | $2.09M | Sell |
274,958
-86,860
| -24% | -$824K | ﹤0.01% | 4492 |
|
|
2021
Q4 | $3.69M | Buy |
361,818
+15,404
| +4% | +$196K | ﹤0.01% | 4036 |
|
|
2021
Q3 | $4.65M | Sell |
346,414
-225,647
| -39% | -$3.68M | ﹤0.01% | 3795 |
|
|
2021
Q2 | $12.6M | Buy |
572,061
+335,635
| +142% | +$7.46M | ﹤0.01% | 2725 |
|
|
2021
Q1 | $5.69M | Buy |
236,426
+2,206
| +0.9% | +$51.3K | ﹤0.01% | 3274 |
|
|
2020
Q4 | $4.21M | Buy |
234,220
+93,868
| +67% | +$1.4M | ﹤0.01% | 3441 |
|
|
2020
Q3 | $1.62M | Buy |
140,352
+97,354
| +226% | +$1.61M | ﹤0.01% | 3842 |
|
|
2020
Q2 | $1.04M | Sell |
42,998
-109,383
| -72% | -$1.81M | ﹤0.01% | 4139 |
|
|
2020
Q1 | $1.68M | Buy |
152,381
+82,547
| +118% | +$1.54M | ﹤0.01% | 3513 |
|
|
2019
Q4 | $1.84M | Sell |
69,834
-91,106
| -57% | -$2.13M | ﹤0.01% | 4108 |
|
|
2019
Q3 | $3.67M | Buy |
160,940
+146,916
| +1,048% | +$4.63M | ﹤0.01% | 3212 |
|
|
2019
Q2 | $430K | Sell |
14,024
-341,718
| -96% | -$7.19M | ﹤0.01% | 4683 |
|
|
2019
Q1 | $5.91M | Buy |
355,742
+149,498
| +72% | +$2.84M | ﹤0.01% | 2546 |
|
|
2018
Q4 | $3.95M | Buy |
206,244
+169,488
| +461% | +$6.35M | ﹤0.01% | 3162 |
|
|
2018
Q3 | $1.92M | Sell |
36,756
-7,116
| -16% | -$388K | ﹤0.01% | 4036 |
|
|
2018
Q2 | $1.91M | Buy |
43,872
+13,232
| +43% | +$567K | ﹤0.01% | 4122 |
|
|
2018
Q1 | $1.14M | Buy |
30,640
+14,551
| +90% | +$388K | ﹤0.01% | 4456 |
|
|
2017
Q4 | $319K | Buy |
16,089
+6,027
| +60% | +$130K | ﹤0.01% | 5223 |
|
|
2017
Q3 | $250K | Buy |
10,062
+8,244
| +453% | +$152K | ﹤0.01% | 5239 |
|
|
2017
Q2 | $32K | Buy |
+1,818
| New | +$31.8K | ﹤0.01% | 5974 |
|
Morgan Stanley's GTHX Position: Q3 2024 in Review
Morgan Stanley sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 401,481 shares — an estimated $915K sold.
Morgan Stanley first reported a position in GTHX in Q2 2017 and held it in 29 quarters. The position peaked at $12.6M in Q2 2021. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- Morgan Stanley reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- Morgan Stanley sold 401,481 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $915K.
- Morgan Stanley first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2017 and held it in 29 quarters.
- Morgan Stanley's G1 Therapeutics, Inc. Common Stock position peaked at $12.6M in Q2 2021.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on Morgan Stanley's 13F filing for Q3 2024, filed 14 Nov 2024.